{
    "id": "d2d333c7-76ee-463d-afeb-c2a7217c29a1",
    "indications": "Hypothyroidism\n                  \n                  Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.\n                  \n                     Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression\n                  \n                  Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.\n                  \n                     Limitations of Use\n                  \n                  \n                     Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.1)].\n                     Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.",
    "contraindications": "Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. ( 2.1 ) Administer at least 4 hours before or after drugs that are known to interfere with absorption. ( 2.1 ) Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. ( 2.1 ) Advise patients to stop biotin and biotin-containing supplements at least 2 days before assessing TSH and/or T4 levels. ( 2.2 ) Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4 to 6 weeks. ( 2.2 ) See full prescribing information for dosing in specific patient populations. ( 2.3 ) Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. ( 2.4 )",
    "warningsAndPrecautions": "Product:    50090-4947\n                  NDC:    50090-4947-0   30 TABLET in a BOTTLE\n                  NDC:    50090-4947-1   90 TABLET in a BOTTLE",
    "adverseReactions": "Levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.4)].",
    "ingredients": [
        {
            "name": "LEVOTHYROXINE SODIUM",
            "code": "9J765S329G"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "KI5",
            "code": "H77VEI93A8"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        }
    ],
    "organization": "A-S Medication Solutions",
    "name": "Levothyroxine Sodium",
    "effectiveTime": "20250522"
}